UCB SA (UCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.52 Billion ≈ $1.78 Billion USD) by net assets (€10.87 Billion ≈ $12.70 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UCB days of operational coverage to measure how many days the company can operate on defensive assets alone.
UCB SA - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
UCB SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
0.018x |
|
Toyota Tsusho Corp
NYSE:TYHOY
|
0.058x |
|
Nu Holdings Ltd
NYSE:NU
|
0.073x |
|
Fifth Third Bancorp
NASDAQ:FITB
|
-0.032x |
|
Mercedes-Benz Group AG
F:MBG
|
0.029x |
|
Franco-Nevada Corporation
TO:FNV
|
0.057x |
|
Kia Corp
KO:000270
|
0.007x |
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
0.309x |
Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)
The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see UCB SA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.87 Billion ≈ $12.70 Billion |
€2.16 Billion ≈ $2.53 Billion |
0.199x | +60.72% |
| 2024-12-31 | €10.03 Billion ≈ $11.72 Billion |
€1.24 Billion ≈ $1.45 Billion |
0.124x | +46.05% |
| 2023-12-31 | €8.97 Billion ≈ $10.49 Billion |
€761.00 Million ≈ $889.69 Million |
0.085x | -31.32% |
| 2022-12-31 | €9.06 Billion ≈ $10.60 Billion |
€1.12 Billion ≈ $1.31 Billion |
0.123x | -33.34% |
| 2021-12-31 | €8.39 Billion ≈ $9.80 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.185x | +24.58% |
| 2020-12-31 | €7.27 Billion ≈ $8.50 Billion |
€1.08 Billion ≈ $1.26 Billion |
0.149x | +18.13% |
| 2019-12-31 | €7.01 Billion ≈ $8.19 Billion |
€882.00 Million ≈ $1.03 Billion |
0.126x | -27.72% |
| 2018-12-31 | €6.25 Billion ≈ $7.31 Billion |
€1.09 Billion ≈ $1.27 Billion |
0.174x | +7.73% |
| 2017-12-31 | €5.74 Billion ≈ $6.71 Billion |
€927.00 Million ≈ $1.08 Billion |
0.162x | +107.29% |
| 2016-12-31 | €5.48 Billion ≈ $6.40 Billion |
€427.00 Million ≈ $499.21 Million |
0.078x | +75.76% |
| 2015-12-31 | €5.55 Billion ≈ $6.48 Billion |
€246.00 Million ≈ $287.60 Million |
0.044x | -60.71% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€552.00 Million ≈ $645.35 Million |
0.113x | +69.44% |
| 2013-12-31 | €4.32 Billion ≈ $5.05 Billion |
€288.00 Million ≈ $336.70 Million |
0.067x | -13.81% |
| 2012-12-31 | €4.59 Billion ≈ $5.37 Billion |
€355.00 Million ≈ $415.03 Million |
0.077x | +27.66% |
| 2011-12-31 | €4.82 Billion ≈ $5.64 Billion |
€292.00 Million ≈ $341.38 Million |
0.061x | -45.06% |
| 2010-12-31 | €4.59 Billion ≈ $5.37 Billion |
€506.00 Million ≈ $591.57 Million |
0.110x | +64.99% |
| 2009-12-31 | €4.42 Billion ≈ $5.16 Billion |
€295.00 Million ≈ $344.89 Million |
0.067x | -26.70% |
| 2008-12-31 | €4.02 Billion ≈ $4.70 Billion |
€366.00 Million ≈ $427.89 Million |
0.091x | -20.71% |
| 2007-12-31 | €4.26 Billion ≈ $4.99 Billion |
€490.00 Million ≈ $572.86 Million |
0.115x | +71.05% |
| 2006-12-31 | €4.78 Billion ≈ $5.59 Billion |
€321.00 Million ≈ $375.28 Million |
0.067x | -44.19% |
| 2005-12-31 | €2.41 Billion ≈ $2.82 Billion |
€290.00 Million ≈ $339.04 Million |
0.120x | -67.06% |
| 2004-12-31 | €1.96 Billion ≈ $2.30 Billion |
€718.17 Million ≈ $839.61 Million |
0.365x | -3.84% |
| 2003-12-31 | €1.78 Billion ≈ $2.09 Billion |
€677.97 Million ≈ $792.61 Million |
0.380x | -0.34% |
| 2002-12-31 | €1.57 Billion ≈ $1.83 Billion |
€596.97 Million ≈ $697.92 Million |
0.381x | +11.99% |
| 2001-12-31 | €1.39 Billion ≈ $1.63 Billion |
€473.45 Million ≈ $553.51 Million |
0.341x | +18.59% |
| 2000-12-31 | €1.21 Billion ≈ $1.41 Billion |
€346.26 Million ≈ $404.81 Million |
0.287x | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more